Trevi Therapeutics is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough in lung disease patients. It last closed at $13.35 on Nov 20, down 2.70% on the day. The next earnings report for TRVI is expected around Tue, Mar 16, 2027, after the close. For the quarter ended Sep 2026, TRVI reported EPS of -$0.13. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months TRVI insiders bought $0 of stock on the open market and sold $596K, according to SEC Form 4 filings.
AI Auto Pilots
Is TRVI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TRVI.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on TRVIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
TRVI · as of the Nov 20 close · updated each morning
Moving sideways
The stock is 3% below its 20 day and 3% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 46). The nearest support is the swing low (Jun 3) at $13.25, and the nearest resistance the Pivot at $13.49.
Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 6.3%/day
Key levels
$20.2252 week high+51.5%
$15.77100 day average+18.1%
$14.75Swing high (May 27)+10.5%
$14.58200 day average+9.2%
$13.76Pivot R1+3.1%
$13.7520 day average+3.0%
$13.7350 day average+2.8%
$13.49Pivot+1.0%
$13.35Last close
$13.25Swing low (Jun 3)−0.7%
$13.09Pivot S1−1.9%
$9.8252 week low−26.4%
Indicators
RSI (14)
46.25
Middle of its range
Neutral
MACD
-0.03
Below its signal line
Bearish
Stochastic
27.3
Middle of its range
Neutral
ADX (14)
18.7
No clear trend
Williams %R
-79.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-38.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−6.8%
Change over 10 sessions
Bearish
ATR (14)
$0.85
Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityLow, 12.7%/day
Key levels
$20.2252 week high+51.5%
$15.77100 day average+18.1%
$14.75Swing high (May 27)+10.5%
$14.58200 day average+9.2%
$13.76Pivot R1+3.1%
$13.7520 day average+3.0%
$13.7350 day average+2.8%
$13.49Pivot+1.0%
$13.35Last close
$13.25Swing low (Jun 3)−0.7%
$13.09Pivot S1−1.9%
$9.8252 week low−26.4%
Indicators
RSI (14)
43.86
Middle of its range
Neutral
MACD
-0.41
Below its signal line
Bearish
Stochastic
27.3
Middle of its range
Neutral
ADX (14)
23.0
Weak trend
Williams %R
-78.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-73.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−16.0%
Change over 10 sessions
Bearish
ATR (14)
$1.70
Typical daily range, 12.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for TRVI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TRVI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow TRVI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for TRVIHow many large options trades hit TRVI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in TRVI in the last 90 days.
From SEC Form 4 filings by TRVI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRVI is in one of them and how their past TRVI trades turned out.
Trevi Therapeutics is a biopharmaceutical company based in New Haven, Connecticut, in the United States. It is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough. The drug is in clinical trials for patients with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough. Nalbuphine has been used as an injectable pain medicine for decades, and the company holds worldwide commercial rights to Haduvio.